MA29171B1 - Formulation a compression directe et procede associe - Google Patents

Formulation a compression directe et procede associe

Info

Publication number
MA29171B1
MA29171B1 MA30104A MA30104A MA29171B1 MA 29171 B1 MA29171 B1 MA 29171B1 MA 30104 A MA30104 A MA 30104A MA 30104 A MA30104 A MA 30104A MA 29171 B1 MA29171 B1 MA 29171B1
Authority
MA
Morocco
Prior art keywords
tablets
direct compression
formulations
new
vildaglipin
Prior art date
Application number
MA30104A
Other languages
English (en)
Inventor
Sabine Pfeffer
Frank Schaefer
Ricardo Schneeberger
Paul Allen Sutton
Martin Friedrich Trueby
Wolfgang Wirth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29171(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29171B1 publication Critical patent/MA29171B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

CETTE INVENTION CONCERNE DES COMPRIMÉS, EN PARTICULIER DES COMPRIMÉS RÉALISÉS PAR COMPRESSION DIRECTE D'UN COMPOSÉ INHIBITEUR DE LA DIPEPTIDYLPEPTIDASE IV (DPP-IV), UN PROCÉDÉ DE PRÉPARATION AFFÉRENT, DE NOUVELLES FORMULATIONS PHARMACEUTIQUES ET DE NOUVELLES POUDRES DE FABRICATION DE COMPRIMÉS RENFERMANT DES FORMULATIONS À BASE D'INHIBITEUR DE DPP-IV CAPABLES D'ÊTRE DIRECTEMENT PRÉPARÉES SOUS FORME DE COMPRIMÉS. L'INVENTION CONCERNE ÉGALEMENT UN PROCÉDÉ DE PRÉPARATION DES COMPRIMÉS QUI CONSISTE À MÉLANGER L'INGRÉDIENT ACTIF AVEC DES EXCIPIENTS SPÉCIFIQUES DANS LES NOUVELLES FORMULATIONS PUIS À PRÉPARER DIRECTEMENT LES FORMULATIONS DANS LES COMPRIMÉS À COMPRESSION DIRECTE. L'INVENTION CONCERNE ÉGALEMENT UNE DISTRIBUTION GRANULOMÉTRIQUE DE VILDAGLIPTINE ET UNE NOUVELLE FORME CRISTALLINE DE VILDAGLIPTINE CONVENANT PARTICULIÈREMENT À LA PRÉPARATION DE COMPRIMÉS AMÉLIORÉS AINSI QUE D'AUTRES COMPOSITIONS PHARMACEUTIQUES.
MA30104A 2005-01-18 2007-07-26 Formulation a compression directe et procede associe MA29171B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64464505P 2005-01-18 2005-01-18
US69048405P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
MA29171B1 true MA29171B1 (fr) 2008-01-02

Family

ID=36581880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30104A MA29171B1 (fr) 2005-01-18 2007-07-26 Formulation a compression directe et procede associe

Country Status (19)

Country Link
US (3) US20080299190A1 (fr)
EP (1) EP1841413A2 (fr)
JP (1) JP2008527004A (fr)
KR (1) KR20070100291A (fr)
AR (1) AR052878A1 (fr)
AU (2) AU2006206670B2 (fr)
BR (1) BRPI0606731A2 (fr)
CA (1) CA2593359A1 (fr)
GT (1) GT200600008A (fr)
IL (1) IL183762A0 (fr)
MA (1) MA29171B1 (fr)
MX (1) MX2007008679A (fr)
NO (1) NO20074048L (fr)
NZ (1) NZ555576A (fr)
PE (1) PE20061017A1 (fr)
RU (1) RU2007131503A (fr)
TN (1) TNSN07274A1 (fr)
TW (1) TW200637616A (fr)
WO (1) WO2006078593A2 (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CN101684089A (zh) * 2004-02-05 2010-03-31 杏林制药株式会社 双环酯类衍生物
EA011290B1 (ru) * 2004-06-17 2009-02-27 Мерц Фарма Гмбх Унд Ко. Кгаа Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
AU2006306420A1 (en) * 2005-10-25 2007-05-03 Merck Sharp & Dohme Corp. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
JP5165582B2 (ja) 2005-12-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルペプチダーゼ−４インヒビターとメトホルミンとを組み合わせた医薬組成物
CA2645154C (fr) 2006-03-08 2011-11-29 Kyorin Pharmaceutical Co., Ltd. Procede de production d'un derive aminoacetylpyrrolidinecarbonitrile et intermediaire utilise pour sa production
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
JP2010518004A (ja) * 2007-02-01 2010-05-27 ネフロジェン， エルエルシー 幹細胞ホーミングの増強および臓器機能障害または臓器不全の治療
EP2123636B1 (fr) 2007-03-22 2012-03-21 Kyorin Pharmaceutical Co., Ltd. Procédé de préparation d'un dérivé d'aminoacétylpyrrolidinecarbonitrile
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
DE102007040952A1 (de) * 2007-08-30 2009-03-05 Miele & Cie. Kg Upright-Staubsauger
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
DK2275108T3 (da) * 2008-05-14 2014-09-08 Sanwa Kagaku Kenkyusho Co Farmaceutisk præparat omfattende en dpp-iv-inhibitor og et andet diabetes-terapimiddel i konkomitant eller kombineret form
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP5476305B2 (ja) 2008-08-07 2014-04-23 杏林製薬株式会社 ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
US20110152342A1 (en) * 2008-08-14 2011-06-23 Hiroshi Uchida Stabilized pharmaceutical composition
EP2326326B1 (fr) 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Inhibiteurs de dpp-4 destinés à l'utilisation dans la cicatrisation des lésions des diabétiques
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
AP2011005794A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof.
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EP2395968B1 (fr) * 2009-02-13 2024-01-17 Boehringer Ingelheim International GmbH Composition pharmaceutique contenant des dérivés de glucopyranosyl diphényl-méthane, sa forme posologique galénique, son procédé de préparation et ses utilisations pour une régulation glycémique améliorée chez un patient
US20120094894A1 (en) 2009-02-13 2012-04-19 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2412370A4 (fr) 2009-03-27 2013-05-22 Kyorin Seiyaku Kk Préparation à libération prolongée de type matrice contenant un additif basique
HUE026133T2 (en) 2009-09-30 2016-05-30 Boehringer Ingelheim Int Process for the preparation of glycopyranosyl substituted benzylbenzene derivatives
IN2012DN02756A (fr) * 2009-09-30 2015-09-18 Boehringer Ingelheim Int
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
EP2566469B1 (fr) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Thérapie combinée
EP2585101A1 (fr) 2010-06-24 2013-05-01 Boehringer Ingelheim International GmbH Thérapie du diabète
CA2816957A1 (fr) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procedes de traitement de la myelofibrose
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
TR201010683A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San. Ve Ti̇c. A.Ş. Vildagliptin formülasyonları.
EP2468268B1 (fr) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Composition de combinaison de vildagliptine et de gliclazide
TR201101809A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20140302150A1 (en) 2011-09-07 2014-10-09 Umit Cifter Dpp-iv inhibitor formulations
EP2572704A1 (fr) 2011-09-22 2013-03-27 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations orodispersibles de la vildagliptine
EP2578208B1 (fr) 2011-10-06 2014-05-21 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations posologiques solides d'inhibiteurs DPP-IV
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2013179300A2 (fr) 2012-05-04 2013-12-05 Megafine Pharma (P) Ltd. Procédé de préparation de vildagliptine et de son intermédiaire
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
AR092843A1 (es) 2012-06-05 2015-05-06 Takeda Pharmaceuticals Co Preparacion solida
WO2014013505A2 (fr) * 2012-07-20 2014-01-23 Hetero Research Foundation Vildagliptine amorphe
EP2769712A1 (fr) * 2013-02-21 2014-08-27 Siegfried International AG Formulation pharmaceutique comportant des agglomérats d'inhibiteur DPP-IV et des particules d'inhibiteur DPP-IV
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
EP3110449B1 (fr) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Utilisation médicale d'un inhibiteur de dpp-4
EP2915528A1 (fr) 2014-03-06 2015-09-09 Sanovel Ilac Sanayi ve Ticaret A.S. Procédé de formulation de vildagliptine sous atmosphère de gaz inerte
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
EP3171710A1 (fr) 2014-07-21 2017-05-31 Roquette Frères Compositions de sucre pour la fabrication de comprimés par compression directe
EP3191024B1 (fr) * 2014-09-11 2020-01-15 Aprevent Medical Inc. Appareil de traitement de l'insuffisance glottique
CN104817482B (zh) * 2015-03-17 2017-05-10 宁波百思佳医药科技有限公司 2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用
WO2017211979A1 (fr) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinaisons de linagliptine et de metformine
WO2018050892A1 (fr) 2016-09-16 2018-03-22 Galenicum Health S.L. Compositions pharmaceutiques de vildagliptine
WO2018092129A1 (fr) 2016-11-15 2018-05-24 The Medical Research,Infrastructure, And Health Services Fund Of The Tel-Aviv Medical Center Dispositif et procédé de réparation de tissu
GR1009406B (el) 2017-10-03 2018-11-26 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου
KR102622198B1 (ko) * 2018-03-30 2024-01-09 한미약품 주식회사 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
WO2019217800A1 (fr) * 2018-05-10 2019-11-14 La'au Pono Réduction en poudre d'extrait de cannabis à usage médical par l'intermédiaire d'une procédure de granulation par voie humide
EP3793529A1 (fr) 2018-05-18 2021-03-24 Galenicum Health S.L.U. Compositions pharmaceutiques stables d'inhibiteurs de dpp-iv en combinaison avec de la metformine sous la forme de comprimés à libération immédiate
GR1009644B (el) 2018-09-25 2019-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
EP4045048A4 (fr) 2019-10-14 2023-05-24 Santa Farma Ilaç Sanayi A.S. Formulations orales comprenant du monohydrate de hci de sitagliptine présentant des caractéristiques pharmaceutiques améliorées
KR102362342B1 (ko) * 2020-01-31 2022-02-14 주식회사 경보제약 빌다글립틴 및 메트포민 포함하는 복합 정제
WO2022003405A1 (fr) 2020-07-03 2022-01-06 Savoi Guilherme Procédé monotope permettant d'obtenir un composé intermédiaire pyrrolidine-2-carbonitrile et procédé télescopique à l'échelle industrielle permettant de préparer du (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptine) l'utilisant
TR202010700A2 (tr) * 2020-07-06 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve en az bi̇r farmasöti̇k olarak kabul edi̇lebi̇li̇r eksi̇pi̇yan i̇çeren bi̇r formülasyon
CN114181129B (zh) * 2021-11-09 2024-02-13 浙江国邦药业有限公司 一种制备不同粒度维格列汀的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
WO2003080056A2 (fr) * 2002-03-21 2003-10-02 Teva Pharmaceutical Industries Ltd. Pioglitazone a particules de taille fine
AU2003262059A1 (en) * 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
CA2519208A1 (fr) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Composition a liberation controlee
PE20050021A1 (es) 2003-04-16 2005-03-15 Novartis Ag Procedimiento para la preparacion de 2-cianopirrolidina n-sustituida
ES2332920T3 (es) * 2004-01-20 2010-02-15 Novartis Ag Proceso y formulacion de compresion directa.
US20090017015A1 (en) * 2004-02-20 2009-01-15 Thomas Edward Hughes Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders

Also Published As

Publication number Publication date
CA2593359A1 (fr) 2006-07-27
EP1841413A2 (fr) 2007-10-10
PE20061017A1 (es) 2006-10-31
WO2006078593A2 (fr) 2006-07-27
IL183762A0 (en) 2008-04-13
MX2007008679A (es) 2007-07-25
AU2006206670A1 (en) 2006-07-27
NO20074048L (no) 2007-10-11
US20060210627A1 (en) 2006-09-21
AR052878A1 (es) 2007-04-11
NZ555576A (en) 2010-12-24
TW200637616A (en) 2006-11-01
KR20070100291A (ko) 2007-10-10
TNSN07274A1 (en) 2008-12-31
RU2007131503A (ru) 2009-05-10
GT200600008A (es) 2006-08-09
AU2006206670B2 (en) 2010-04-15
AU2010201312A1 (en) 2010-04-22
US20080299190A1 (en) 2008-12-04
US20120015029A1 (en) 2012-01-19
BRPI0606731A2 (pt) 2009-07-14
JP2008527004A (ja) 2008-07-24
WO2006078593A3 (fr) 2006-09-14

Similar Documents

Publication Publication Date Title
MA29171B1 (fr) Formulation a compression directe et procede associe
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200738280A (en) Novel pharmaceutical compositions comprising levetiracetam and process for their preparation
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
MY142109A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MA31797B1 (fr) Compositions pharmaceutiques
TW200736258A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
IL179718A0 (en) Pharmaceutical composition containing irbesartan
MA29909B1 (fr) Derives de pyridazine
MXPA05014082A (es) Acidos biariloximetilarenocarboxilicos.
WO2004078105A3 (fr) Composition de fondaparinux sodique de haute purete
TW200514772A (en) Novel tetrahydropyridine derivatives
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
TNSN07013A1 (en) Anti-histaminic composition
WO2007075838A3 (fr) Bromure de tiotropium pur et stable
EP1831239B8 (fr) Procédé de synthèse de la gamma-lactone de l'acide 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bisméthylène -17 alpha- pregn-4- ène-3-one-21 carboxylique et intermédiaries-clés de ce procédé
RS11304A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
WO2005058890A3 (fr) Derives d'hydronopol utilises comme agonistes des recepteurs orl1 humains
UA93355C2 (ru) Композиция субероиланилид-гидроксаминовой кислоты и способы ee получения
MY144613A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
YU64001A (sh) Jedinjenja betahistina sa kontrolisanim oslobadjanjem
TW200640860A (en) Lercanidipine free base
AU2003208599A1 (en) Fosinopril formulation
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1